Trastuzumab-qyyp (Trazimera™)

Author: OncoLink Team
Last Reviewed: June 25, 2019

Pronounced: tras-TOOZ-oo-mab qyyp

Classification: Monoclonal Antibody

About: Trastuzumab-qyyp (Trazimera™)

Monoclonal antibodies are created in a lab to attach to the targets found on specific types of cancer cells. The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth or other functions necessary for cell growth. Trastuzumab-qyyp is thought to block these receptors, preventing them from turning on cell growth.

Trastuzumab-qyyp is a type of monoclonal antibody which targets HER-2 positive breast cancer cells. HER2 is overexpressed on some breast cancers. HER2 receptors on cells send signals telling the cell to grow and divide. Cancers that overexpress HER2 have too many receptors, which cause the cells to grow and divide more quickly. By inhibiting HER2, signals are sent to these cells to slow their growth.

This medication is a biosimilar. A biosimilar is a medication that has been approved by the FDA because it is very similar to an FDA-approved medication (called a reference product, or the medication it is being compared to). There are no meaningful differences between the biosimilar product and the reference product and they work the same.

How to Take Trastuzumab-qyyp 

Trastuzumab-qyyp is given by intravenous (IV, into a vein) infusion. The dose is based on your weight. The initial infusion generally takes about 90 minutes, and subsequent treatments may take 30-90 minutes. The dose is based on your body size and type of cancer. The frequency of doses and adjuvant chemotherapy depends on the regimen used. Because trastuzumab-qyyp is indicated only for treatment of HER2 positive cancer, a sample of your tumor will be tested in a lab to determine if it is HER2 positive prior to starting treatment.

Possible Side Effects of Trastuzumab-qyyp 

There are a number of things you can do to manage the side effects of trastuzumab-qyyp. Talk to your doctor or nurse about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:

Heart Problems

Trastuzumab-qyyp can cause heart problems, or worsen pre-existing heart problems, including congestive heart failure. Your heart function will be tested using a echocardiogram or MUGA scan prior to starting treatment with trastuzumab-qyyp, and every couple of months while on treatment and after completion of treatment. Notify your healthcare provider if you have a sudden weight gain or swelling in the ankles or legs. If heart function decreases, trastuzumab-qyyp will be stopped. The risk of heart problems is greater when trastuzumab-qyyp is given in combination with anthracycline chemotherapy medications.

Infusion-Related Side Effects

Some patients experience chills and fever within 24 hours of the first infusion. The first trastuzumab-qyyp infusion can also cause the patient to have nausea/vomiting, pain, headache, dizziness, and rash. For these reactions, the infusion will be stopped, acetaminophen and/or diphenhydramine given to lessen the reactions, and the infusion restarted at a slower rate once symptoms resolve. This typically does not happen with subsequent infusions.

More serious reactions can occur, but are rare. Symptoms of a serious reaction include: shortness of breath, wheezing, low blood pressure, and increase in heart rate. The infusion will be stopped if this happens and your provider will determine whether or not it is safe to restart the infusion. Notify your nurse right away if you develop any concerning symptoms.

Lung Problems

Trastuzumab-qyyp use can cause toxicity to the lungs, including swelling, fluid and/or scarring within the lungs. You should report any new or worsening shortness of breath, trouble breathing, cough, or fever to your care team as these may be signs of lung toxicity.

Low White Blood Cell Count (Leukopenia or Neutropenia) 

White blood cells (WBC) are important for fighting infection. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. You should let your doctor or nurse know right away if you have a fever (temperature greater than 100.4°F or 38°C), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal.

Tips to preventing infection:

  • Washing hands, both yours and your visitors, is the best way to prevent the spread of infection.
  • Avoid large crowds and people who are sick (i.e.: those who have a cold, fever or cough or live with someone with these symptoms).
  • When working in your yard, wear protective clothing including long pants and gloves.
  • Do not handle pet waste.
  • Keep all cuts or scratches clean.
  • Shower or bath daily and perform frequent mouth care.
  • Do not cut cuticles or ingrown nails. You may wear nail polish, but not fake nails.
  • Ask your oncology care team before scheduling dental appointments or procedures.
  • Ask your oncology care team before you, or someone you live with, has any vaccinations.

Fatigue

Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.

Nausea and/or Vomiting

Talk to your oncology care team so they can prescribe medications to help you manage nausea and vomiting. In addition, dietary changes may help. Avoid things that may worsen the symptoms, such as heavy or greasy/fatty, spicy or acidic foods (lemons, tomatoes, oranges). Try saltines, or ginger ale to lessen symptoms.

Call your oncology care team if you are unable to keep fluids down for more than 12 hours or if you feel lightheaded or dizzy at any time.

Diarrhea

Your oncology team can recommend medications to relieve diarrhea. Also, try eating low-fiber, bland foods, such as white rice and boiled or baked chicken. Avoid raw fruits, vegetables, whole grain breads, cereals and seeds. Soluble fiber is found in some foods and absorbs fluid, which can help relieve diarrhea. Foods high in soluble fiber include: applesauce, bananas (ripe), canned fruit, orange sections, boiled potatoes, white rice, products made with white flour, oatmeal, cream of rice, cream of wheat, and farina. Drink 8-10 glasses on non-alcoholic, un-caffeinated fluid a day to prevent dehydration. 

Less common but important side effects can include:

  • Kidney problems: this medication can cause a decrease in kidney function or damage to the kidney. For this reason, your healthcare team will monitor your kidney function with blood tests while receiving trastuzumab-qyyp. Some patients will need to stop the medication due to kidney function changes. Notify your provider if you notice any blood in your urine, decrease in urination or darkening of the urine.

Reproductive Concerns

Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. Effective birth control is necessary during treatment and for at least 7 months after treatment. Even if your menstrual cycle stops or you believe you are not producing sperm, you could still be fertile and conceive. If you become pregnant within 7 months of stopping this medication inform your care provider immediately. You should not breastfeed while receiving this medication.

Keywords

Click on any of these terms for more related articles

Blogs

Answering the Call of Oncology Nursing
by OncoLink Team
May 21, 2019

Social Work Stories: Jean
by Christina Bach, MSW, LCSW, OSW-C
March 20, 2019

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives